カテゴリー： QYResearch, 世界, 医療/バイオ

結核病ワクチンのグローバル市場2023年：予防ワクチン、曝露後ワクチン、その他

◆英語タイトル：Global TB Disease Vaccine Market Research Report 2023

QYResearchが発行した調査報告書（QYR23MA8902）◆商品コード：QYR23MA8902
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2023年3月
◆ページ数：93
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の結核病ワクチン市場について調査・分析し、世界の結核病ワクチン市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（予防ワクチン、曝露後ワクチン、その他）、用途別セグメント分析（自己調達、ユニセフ、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Merck、Japan BCG Lab、Serum Institute of India、AJ Vaccines、BioFarma、GreenSignal Bio Pharma、China National Biotec、Biomed Lublin、Taj Pharmaceuticals、Ataulpho de Paiva、IVAC、Queen Saovabha Mem. Inst、Microgenなどが含まれています。世界の結核病ワクチン市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、結核病ワクチン市場規模を推定する際に考慮しました。

・結核病ワクチン市場の概要
- 製品の定義
- 結核病ワクチンのタイプ別セグメント
- 世界の結核病ワクチン市場規模：タイプ別分析（予防ワクチン、曝露後ワクチン、その他）
- 結核病ワクチンの用途別セグメント
- 世界の結核病ワクチン市場規模：用途別分析（自己調達、ユニセフ、その他）
- 世界の結核病ワクチン市場規模予測（2018年-2029年）
- 結核病ワクチンの平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 結核病ワクチン市場の競争状況およびトレンド

・結核病ワクチンの地域別市場規模
- 北米の結核病ワクチン市場規模（2018年-2029年）
- アメリカの結核病ワクチン市場規模（2018年-2029年）
- ヨーロッパの結核病ワクチン市場規模（2018年-2029年）
- アジア太平洋の結核病ワクチン市場規模（2018年-2029年）
- 中国の結核病ワクチン市場規模（2018年-2029年）
- 日本の結核病ワクチン市場規模（2018年-2029年）
- 韓国の結核病ワクチン市場規模（2018年-2029年）
- インドの結核病ワクチン市場規模（2018年-2029年）
- オーストラリアの結核病ワクチン市場規模（2018年-2029年）
- 中南米の結核病ワクチン市場規模（2018年-2029年）
- 中東・アフリカの結核病ワクチン市場規模（2018年-2029年）

・タイプ別セグメント：予防ワクチン、曝露後ワクチン、その他
- 世界の結核病ワクチンのタイプ別販売量（2018年-2023年）
- 世界の結核病ワクチンのタイプ別売上（2018年-2023年）
- 世界の結核病ワクチンのタイプ別価格

・用途別セグメント：自己調達、ユニセフ、その他
- 世界の結核病ワクチンの用途別販売量（2018年-2023年）
- 世界の結核病ワクチンの用途別売上（2018年-2023年）
- 世界の結核病ワクチンの用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Merck、Japan BCG Lab、Serum Institute of India、AJ Vaccines、BioFarma、GreenSignal Bio Pharma、China National Biotec、Biomed Lublin、Taj Pharmaceuticals、Ataulpho de Paiva、IVAC、Queen Saovabha Mem. Inst、Microgen

・産業チェーンと販売チャネルの分析
- 結核病ワクチン産業チェーン分析
- 結核病ワクチンの主要原材料
- 結核病ワクチンの販売チャネル
- 結核病ワクチンのディストリビューター
- 結核病ワクチンの主要顧客

・結核病ワクチン市場ダイナミクス
- 結核病ワクチンの業界動向
- 結核病ワクチン市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

The vaccine for tuberculosis (TB) is known as BCG (bacille Calmette-Guérin) vaccine. BCG vaccine contains a weakened form of the bacteria (germ) that cause TB. Because it is weakened it doesn’t cause TB in healthy people but it helps develop some protection (immunity) against TB.
Highlights
The global TB Disease Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for TB Disease Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for TB Disease Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of TB Disease Vaccine include Merck, Japan BCG Lab, Serum Institute of India, AJ Vaccines, BioFarma, GreenSignal Bio Pharma, China National Biotec, Biomed Lublin and Taj Pharmaceuticals, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for TB Disease Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding TB Disease Vaccine.
The TB Disease Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global TB Disease Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the TB Disease Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC
Queen Saovabha Mem. Inst
Microgen
Segment by Type
Prevention Vaccines
Post-exposure Vaccines
Others
Segment by Application
Self-Procurement
UNICEF
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of TB Disease Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of TB Disease Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 TB Disease Vaccine Market Overview
1.1 Product Overview and Scope of TB Disease Vaccine
1.2 TB Disease Vaccine Segment by Type
1.2.1 Global TB Disease Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Prevention Vaccines
1.2.3 Post-exposure Vaccines
1.2.4 Others
1.3 TB Disease Vaccine Segment by Application
1.3.1 Global TB Disease Vaccine Market Value by Application: (2023-2029)
1.3.2 Self-Procurement
1.3.3 UNICEF
1.3.4 Others
1.4 Global TB Disease Vaccine Market Size Estimates and Forecasts
1.4.1 Global TB Disease Vaccine Revenue 2018-2029
1.4.2 Global TB Disease Vaccine Sales 2018-2029
1.4.3 Global TB Disease Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 TB Disease Vaccine Market Competition by Manufacturers
2.1 Global TB Disease Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global TB Disease Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global TB Disease Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global TB Disease Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of TB Disease Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of TB Disease Vaccine, Product Type & Application
2.7 TB Disease Vaccine Market Competitive Situation and Trends
2.7.1 TB Disease Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest TB Disease Vaccine Players Market Share by Revenue
2.7.3 Global TB Disease Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 TB Disease Vaccine Retrospective Market Scenario by Region
3.1 Global TB Disease Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global TB Disease Vaccine Global TB Disease Vaccine Sales by Region: 2018-2029
3.2.1 Global TB Disease Vaccine Sales by Region: 2018-2023
3.2.2 Global TB Disease Vaccine Sales by Region: 2024-2029
3.3 Global TB Disease Vaccine Global TB Disease Vaccine Revenue by Region: 2018-2029
3.3.1 Global TB Disease Vaccine Revenue by Region: 2018-2023
3.3.2 Global TB Disease Vaccine Revenue by Region: 2024-2029
3.4 North America TB Disease Vaccine Market Facts & Figures by Country
3.4.1 North America TB Disease Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America TB Disease Vaccine Sales by Country (2018-2029)
3.4.3 North America TB Disease Vaccine Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe TB Disease Vaccine Market Facts & Figures by Country
3.5.1 Europe TB Disease Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe TB Disease Vaccine Sales by Country (2018-2029)
3.5.3 Europe TB Disease Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific TB Disease Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific TB Disease Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific TB Disease Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific TB Disease Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America TB Disease Vaccine Market Facts & Figures by Country
3.7.1 Latin America TB Disease Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America TB Disease Vaccine Sales by Country (2018-2029)
3.7.3 Latin America TB Disease Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa TB Disease Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa TB Disease Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa TB Disease Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa TB Disease Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global TB Disease Vaccine Sales by Type (2018-2029)
4.1.1 Global TB Disease Vaccine Sales by Type (2018-2023)
4.1.2 Global TB Disease Vaccine Sales by Type (2024-2029)
4.1.3 Global TB Disease Vaccine Sales Market Share by Type (2018-2029)
4.2 Global TB Disease Vaccine Revenue by Type (2018-2029)
4.2.1 Global TB Disease Vaccine Revenue by Type (2018-2023)
4.2.2 Global TB Disease Vaccine Revenue by Type (2024-2029)
4.2.3 Global TB Disease Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global TB Disease Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global TB Disease Vaccine Sales by Application (2018-2029)
5.1.1 Global TB Disease Vaccine Sales by Application (2018-2023)
5.1.2 Global TB Disease Vaccine Sales by Application (2024-2029)
5.1.3 Global TB Disease Vaccine Sales Market Share by Application (2018-2029)
5.2 Global TB Disease Vaccine Revenue by Application (2018-2029)
5.2.1 Global TB Disease Vaccine Revenue by Application (2018-2023)
5.2.2 Global TB Disease Vaccine Revenue by Application (2024-2029)
5.2.3 Global TB Disease Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global TB Disease Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck TB Disease Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Japan BCG Lab
6.2.1 Japan BCG Lab Corporation Information
6.2.2 Japan BCG Lab Description and Business Overview
6.2.3 Japan BCG Lab TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Japan BCG Lab TB Disease Vaccine Product Portfolio
6.2.5 Japan BCG Lab Recent Developments/Updates
6.3 Serum Institute of India
6.3.1 Serum Institute of India Corporation Information
6.3.2 Serum Institute of India Description and Business Overview
6.3.3 Serum Institute of India TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Serum Institute of India TB Disease Vaccine Product Portfolio
6.3.5 Serum Institute of India Recent Developments/Updates
6.4 AJ Vaccines
6.4.1 AJ Vaccines Corporation Information
6.4.2 AJ Vaccines Description and Business Overview
6.4.3 AJ Vaccines TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 AJ Vaccines TB Disease Vaccine Product Portfolio
6.4.5 AJ Vaccines Recent Developments/Updates
6.5 BioFarma
6.5.1 BioFarma Corporation Information
6.5.2 BioFarma Description and Business Overview
6.5.3 BioFarma TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 BioFarma TB Disease Vaccine Product Portfolio
6.5.5 BioFarma Recent Developments/Updates
6.6 GreenSignal Bio Pharma
6.6.1 GreenSignal Bio Pharma Corporation Information
6.6.2 GreenSignal Bio Pharma Description and Business Overview
6.6.3 GreenSignal Bio Pharma TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 GreenSignal Bio Pharma TB Disease Vaccine Product Portfolio
6.6.5 GreenSignal Bio Pharma Recent Developments/Updates
6.7 China National Biotec
6.6.1 China National Biotec Corporation Information
6.6.2 China National Biotec Description and Business Overview
6.6.3 China National Biotec TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 China National Biotec TB Disease Vaccine Product Portfolio
6.7.5 China National Biotec Recent Developments/Updates
6.8 Biomed Lublin
6.8.1 Biomed Lublin Corporation Information
6.8.2 Biomed Lublin Description and Business Overview
6.8.3 Biomed Lublin TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Biomed Lublin TB Disease Vaccine Product Portfolio
6.8.5 Biomed Lublin Recent Developments/Updates
6.9 Taj Pharmaceuticals
6.9.1 Taj Pharmaceuticals Corporation Information
6.9.2 Taj Pharmaceuticals Description and Business Overview
6.9.3 Taj Pharmaceuticals TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Taj Pharmaceuticals TB Disease Vaccine Product Portfolio
6.9.5 Taj Pharmaceuticals Recent Developments/Updates
6.10 Ataulpho de Paiva
6.10.1 Ataulpho de Paiva Corporation Information
6.10.2 Ataulpho de Paiva Description and Business Overview
6.10.3 Ataulpho de Paiva TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Ataulpho de Paiva TB Disease Vaccine Product Portfolio
6.10.5 Ataulpho de Paiva Recent Developments/Updates
6.11 IVAC
6.11.1 IVAC Corporation Information
6.11.2 IVAC TB Disease Vaccine Description and Business Overview
6.11.3 IVAC TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 IVAC TB Disease Vaccine Product Portfolio
6.11.5 IVAC Recent Developments/Updates
6.12 Queen Saovabha Mem. Inst
6.12.1 Queen Saovabha Mem. Inst Corporation Information
6.12.2 Queen Saovabha Mem. Inst TB Disease Vaccine Description and Business Overview
6.12.3 Queen Saovabha Mem. Inst TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Queen Saovabha Mem. Inst TB Disease Vaccine Product Portfolio
6.12.5 Queen Saovabha Mem. Inst Recent Developments/Updates
6.13 Microgen
6.13.1 Microgen Corporation Information
6.13.2 Microgen TB Disease Vaccine Description and Business Overview
6.13.3 Microgen TB Disease Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Microgen TB Disease Vaccine Product Portfolio
6.13.5 Microgen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 TB Disease Vaccine Industry Chain Analysis
7.2 TB Disease Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 TB Disease Vaccine Production Mode & Process
7.4 TB Disease Vaccine Sales and Marketing
7.4.1 TB Disease Vaccine Sales Channels
7.4.2 TB Disease Vaccine Distributors
7.5 TB Disease Vaccine Customers
8 TB Disease Vaccine Market Dynamics
8.1 TB Disease Vaccine Industry Trends
8.2 TB Disease Vaccine Market Drivers
8.3 TB Disease Vaccine Market Challenges
8.4 TB Disease Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 結核病ワクチンのグローバル市場2023年：予防ワクチン、曝露後ワクチン、その他(Global TB Disease Vaccine Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 世界の呼吸器疾患用ワクチン市場（2023-2030）：種類別（ウイルスワクチン、細菌ワクチン、混合ワクチン）、年齢層別（小児、成人）、感染症別（新型コロナウイルス、インフルエンザ、呼吸器合胞体ウイルス（RSV）、肺炎、その他）、流通チャネル別（病院＆小売薬局、政府供給業者、その他）、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆